Top

Published in:

01-10-2010 | Original Article

Generation of recombinant European bat lyssavirus type 1 and inter-genotypic compatibility of lyssavirus genotype 1 and 5 antigenome promoters

Authors: Jeannette Orbanz, Stefan Finke

Published in: Archives of Virology | Issue 10/2010

Abstract

Bat lyssaviruses (Fam. Rhabdoviridae) represent a source for the infection of terrestial mammals and the development of rabies disease. Molecular differences in the replication of bat and non-bat lyssaviruses and their contribution to pathogenicity, however, are unknown. One reason for this is the lack of reverse genetics systems for bat-restricted lyssaviruses. To investigate bat lyssavirus replication and host adaptation, we developed a reverse genetics system for European bat lyssavirus type 1 (EBLV-1; genotype 5). This was achieved by co-transfection of HEK-293T cells with a full-length EBLV-1 genome cDNA and expression plasmids for EBLV-1 proteins, resulting in recombinant EBLV-1 (rEBLV-1). Replication of rEBLV-1 was comparable to that of parental virus, showing that rEBLV-1 is a valid tool to investigate EBLV-1 replication functions. In a first approach, we tested whether the terminal promoter sequences of EBLV-1 are genotype-specific. Although genotype 1 (rabies virus) minigenomes were successfully amplified by EBLV-1 helper virus, in the context of the complete virus, only the antigenome promoter (AGP) sequence of EBLV-1 was replaceable, as indicated by comparable replication of rEBLV-1 and the chimeric virus. These analyses demonstrate that the terminal AGPs of genotype 1 and genotype 5 lyssaviruses are compatible with those of the heterologous genotype.

Available only for authorised users

Badrane H, Tordo N (2001) Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 75:8096–8104CrossRefPubMed

Brookes SM, Klopfleisch R, Muller T, Healy DM, Teifke JP, Lange E, Kliemt J, Johnson N, Johnson L, Kaden V, Vos A, Fooks AR (2007) Susceptibility of sheep to European bat lyssavirus type-1 and -2 infection: a clinical pathogenesis study. Vet Microbiol 125:210–223CrossRefPubMed

Brzozka K, Finke S, Conzelmann KK (2005) Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J Virol 79:7673–7681CrossRefPubMed

Brzozka K, Finke S, Conzelmann KK (2006) Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol 80:2675–2683CrossRefPubMed

Cliquet F, Picard-Meyer E, Barrat J, Brookes SM, Healy DM, Wasniewski M, Litaize E, Biarnais M, Johnson L, Fooks AR (2009) Experimental infection of Foxes with European bat Lyssaviruses type-1 and 2. BMC Vet Res 5:19CrossRefPubMed

Davis PL, Holmes EC, Larrous F, Van der Poel WH, Tjornehoj K, Alonso WJ, Bourhy H (2005) Phylogeography, population dynamics, and molecular evolution of European bat lyssaviruses. J Virol 79:10487–10497CrossRefPubMed

Delmas O, Holmes EC, Talbi C, Larrous F, Dacheux L, Bouchier C, Bourhy H (2008) Genomic diversity and evolution of the lyssaviruses. PLoS ONE 3:e2057CrossRefPubMed

Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B (2002) Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol 76:3374–3381CrossRefPubMed

Faber M, Pulmanausahakul R, Nagao K, Prosniak M, Rice AB, Koprowski H, Schnell MJ, Dietzschold B (2004) Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci USA 101:16328–16332CrossRefPubMed

10.

Finke S, Conzelmann KK (2003) Dissociation of rabies virus matrix protein functions in regulation of viral RNA synthesis and virus assembly. J Virol 77:12074–12082CrossRefPubMed

11.

Finke S, Conzelmann KK (1997) Ambisense gene expression from recombinant rabies virus: random packaging of positive- and negative-strand ribonucleoprotein complexes into rabies virions. J Virol 71:7281–7288PubMed

12.

Finke S, Conzelmann KK (1999) Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3′ copy-back ambisense rabies virus. J Virol 73:3818–3825PubMed

13.

Finke S, Cox JH, Conzelmann KK (2000) Differential transcription attenuation of rabies virus genes by intergenic regions: generation of recombinant viruses overexpressing the polymerase gene. J Virol 74:7261–7269CrossRefPubMed

14.

Finke S, Granzow H, Hurst J, Pollin R, Mettenleiter TC (2010) Intergenotypic replacement of lyssavirus matrix proteins demonstrates the role of lyssavirus M proteins in intracellular virus accumulation. J Virol 84:1816–1827CrossRefPubMed

15.

Finke S, Mueller-Waldeck R, Conzelmann KK (2003) Rabies virus matrix protein regulates the balance of virus transcription and replication. J Gen Virol 84:1613–1621CrossRefPubMed

16.

Fooks AR, McElhinney LM, Pounder DJ, Finnegan CJ, Mansfield K, Johnson N, Brookes SM, Parsons G, White K, McIntyre PG, Nathwani D (2003) Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis. J Med Virol 71:281–289CrossRefPubMed

17.

Gholami A, Kassis R, Real E, Delmas O, Guadagnini S, Larrous F, Obach D, Prevost MC, Jacob Y, Bourhy H (2008) Mitochondrial dysfunction in lyssavirus-induced apoptosis. J Virol 82:4774–4784CrossRefPubMed

18.

Inoue K, Shoji Y, Kurane I, Iijima T, Sakai T, Morimoto K (2003) An improved method for recovering rabies virus from cloned cDNA. J Virol Methods 107:229–236CrossRefPubMed

19.

Jacob Y, Badrane H, Ceccaldi PE, Tordo N (2000) Cytoplasmic dynein LC8 interacts with lyssavirus phosphoprotein. J Virol 74:10217–10222CrossRefPubMed

20.

Kassis R, Larrous F, Estaquier J, Bourhy H (2004) Lyssavirus matrix protein induces apoptosis by a TRAIL-dependent mechanism involving caspase-8 activation. J Virol 78:6543–6555CrossRefPubMed

21.

Kuzmin IV, Wu X, Tordo N, Rupprecht CE (2008) Complete genomes of Aravan, Khujand, Irkut and West Caucasian bat viruses, with special attention to the polymerase gene and non-coding regions. Virus Res 136:81–90CrossRefPubMed

22.

Le MP, Jacob Y, Tanner K, Tordo N (2002) A novel expression cassette of lyssavirus shows that the distantly related Mokola virus can rescue a defective rabies virus genome. J Virol 76:2024–2027CrossRef

23.

Lumio J, Hillbom M, Roine R, Ketonen L, Haltia M, Valle M, Neuvonen E, Lahdevirta J (1986) Human rabies of bat origin in Europe. Lancet 1:378CrossRefPubMed

24.

Marston DA, McElhinney LM, Johnson N, Muller T, Conzelmann KK, Tordo N, Fooks AR (2007) Comparative analysis of the full genome sequence of European bat lyssavirus type 1 and type 2 with other lyssaviruses and evidence for a conserved transcription termination and polyadenylation motif in the G-L 3′ non-translated region. J Gen Virol 88:1302–1314CrossRefPubMed

25.

Martin A, Staeheli P, Schneider U (2006) RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 80:5708–5715CrossRefPubMed

26.

Morimoto K, Hooper DC, Spitsin S, Koprowski H, Dietzschold B (1999) Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J Virol 73:510–518PubMed

27.

Muller T, Cox J, Peter W, Schafer R, Johnson N, McElhinney LM, Geue JL, Tjornehoj K, Fooks AR (2004) Spill-over of European bat lyssavirus type 1 into a stone marten (Martes foina) in Germany. J Vet Med B Infect Dis Vet Public Health 51:49–54PubMed

28.

Nadin-Davis SA, Abdel-Malik M, Armstrong J, Wandeler AI (2002) Lyssavirus P gene characterisation provides insights into the phylogeny of the genus and identifies structural similarities and diversity within the encoded phosphoprotein. Virology 298:286–305CrossRefPubMed

29.

Nathwani D, McIntyre PG, White K, Shearer AJ, Reynolds N, Walker D, Orange GV, Fooks AR (2003) Fatal human rabies caused by European bat Lyssavirus type 2a infection in Scotland. Clin Infect Dis 37:598–601CrossRefPubMed

30.

Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–199CrossRefPubMed

31.

Prehaud C, Lay S, Dietzschold B, Lafon M (2003) Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis. J Virol 77:10537–10547CrossRefPubMed

32.

Raux H, Flamand A, Blondel D (2000) Interaction of the rabies virus P protein with the LC8 dynein light chain. J Virol 74:10212–10216CrossRefPubMed

33.

Schnell MJ, Mebatsion T, Conzelmann KK (1994) Infectious rabies viruses from cloned cDNA. EMBO J 13:4195–4203PubMed

34.

Tjornehoj K, Fooks AR, Agerholm JS, Ronsholt L (2006) Natural and experimental infection of sheep with European bat lyssavirus type-1 of Danish bat origin. J Comp Pathol 134:190–201CrossRefPubMed

35.

Vidy A, Chelbi-Alix M, Blondel D (2005) Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol 79:14411–14420CrossRefPubMed

36.

Vidy A, El BJ, Chelbi-Alix MK, Blondel D (2007) The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1. J Virol 81:4255–4263CrossRefPubMed

37.

Vos A, Muller T, Cox J, Neubert L, Fooks AR (2004) Susceptibility of ferrets (Mustela putorius furo) to experimentally induced rabies with European Bat Lyssaviruses (EBLV). J Vet Med B Infect Dis Vet Public Health 51:55–60PubMed

38.

Vos A, Muller T, Neubert L, Zurbriggen A, Botteron C, Pohle D, Schoon H, Haas L, Jackson AC (2004) Rabies in red foxes (Vulpes vulpes) experimentally infected with European bat lyssavirus type 1. J Vet Med B Infect Dis Vet Public Health 51:327–332PubMed

Title: Generation of recombinant European bat lyssavirus type 1 and inter-genotypic compatibility of lyssavirus genotype 1 and 5 antigenome promoters
Authors: Jeannette Orbanz
Stefan Finke
Publication date: 01-10-2010
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 10/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-010-0743-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2010

Characterization of Rhynchosia yellow mosaic Yucatan virus, a new recombinant begomovirus associated with two fabaceous weeds in Yucatan, Mexico

Molecular characterization of adenovirus detected from fecal samples obtained from children in the Central West region of Brazil

Characterization of a filamentous virus from Bermuda grass and its molecular, serological and biological comparison with Spartina mottle virus

Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry

Rapid detection of tobacco mosaic virus using the reverse transcription loop-mediated isothermal amplification method

Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials